Medicinal Products

DOPERGINE 0.5 mg

Generic Drug Therapeutic Class: Neurology-Psychiatry
active ingredients: Lisuride
laboratory: Bayer Sante

Tablet breackable
Box of 1 bottle of 30
All forms

Indication

Parkinson disease

· Early association with dopa therapy with the aim of decreasing the dose of each of the active products and delaying the appearance of fluctuations in efficacy and abnormal movements.

· Association in the course of evolution of the disease when the effect of the dopathatherapy is exhausted or becomes inconstant and that appear fluctuations of the therapeutic effect (fluctuations of the type "end of dose" or effect "on-off" ).

The combination of DOPERGINE with levodopa should be carried out gradually with the possibility of reducing the doses of levodopa (see section Dosage and method of administration ).

Dosage DOPERGINE 0.5 mg Breakable tablet Box of 1 Bottle of 30

Dosage

To improve digestive tolerance, medication should always be given during meals or a snack.

To split a tablet in half, place the tablet on a hard surface with the notched side facing down and press the tablet with your thumb.

Parkinson disease

The dose must be adapted individually, depending on the efficacy and tolerance.

The dosage should be slowly progressive according to the following treatment regimen:

· Start treatment with half a tablet of DOPERGINE 0.2 mg in the evening,

· Gradually increase the doses in increments of 0.1 mg, ie ½ tablet per week, to start again in one to 4 doses daily, at the time of the meals.

Week

tablets

1

2

3

4

5

6

7

8

morning

-

½

½

½

½

1

1

1

midday

-

-

½

½

½

½

1

1

afternoon

-

-

-

½

½

½

½

1

evening

½

½

½

½

1

1

1

1

Average effective dosages are generally:

· 1 mg daily (between 0.8 and 1.2 mg) for early association with levodopa;

· 2 mg daily (between 1 and 5 mg) for late association in patients with Parkinson's disease with impaired action of dopathapy.

From 2 mg per day, use 0.5 mg tablets.

It is preferable to divide the daily doses in 3 to 4 doses and even more in case of marked fluctuations.

In addition to increasing the dose of DOPERGINE, the dose of levodopa may be reduced by approximately 20%. Particular dose monitoring should be exercised when levodopa is co-administered with selegiline (monoamino oxidase inhibitor), which increases and prolongs dopamine activity.

After each dose increase, the therapeutic effect obtained and the tolerance should be observed for at least one week before considering a further increase.

If the clinical picture makes it desirable to start treatment with DOPERGINE quickly, domperidone can be given to reduce the side effects (nausea, dizziness, headache, fatigue). This must however be the exception. Do not prolong the addition of domperidone beyond 4 weeks. If symptoms persist, it is desirable to reduce the doses of DOPERGINE.

Against indications

· Hypersensitivity to lisuride maleate, other ergot alkaloids or any of the excipients.

· Combination with anti- emetic neuroleptics, phenylpropanolamine (see section 4.5 ).

· Although no vascular action of DOPERGINE has been demonstrated so far, the indication should be rigorously applied in patients with severe peripheral and cardiac arterial circulatory disorders (insufficiency). coronary).

· In patients who have or have had a history of mental disorders (intellectual deterioration, confusional attacks, visual hallucinations) or psychiatric disorders, the indication should be made by weighing the expected benefit against the risk incurred, as it can not be Exclude a worsening of the clinical picture or the reappearance of symptoms.

Dopergine side effects

Those dopamine agonists:

Digestive disorders (nausea, vomiting, headache) may occur more particularly at the beginning of treatment. They can be improved or prevented by taking domperidone.

The occurrence of orthostatic hypotension is possible. Exceptionally, a collapse may occur.

Psychic disturbances (confusion, hallucinations, delusions, psychomotor excitement) can be observed, especially at high doses and mainly in patients with a psychiatric history (see sections Contraindications and special warnings and precautions for use ).

Cases of pathological gambling (compulsive gambling), hypersexuality and increased libido have been reported since marketing (see section 4.4 ).

Weight gain has been described in some Parkinson patients.

Heart conditions

Very rarely: pericarditis and pericardial effusion have been reported.

In patients treated with ergot derivatives, cases of cardiac valvulopathy (including regurgitation) have been reported.

The occurrence of pleuro-pulmonary fibrosis (fibrosis, effusion) or retroperitoneal fibrosis has been observed in isolated cases after long-term use of dopaminergic agonists including DOPERGINE. The occurrence of dyspnoea, persistent coughing, coughing, increased serum creatinine during treatment should lead to a diagnosis and, if necessary, cessation of treatment.

Also reported: decreased alertness, dryness of the mouth, constipation, cutaneous or mucosal reactions of allergic type and oedemas of the lower limbs.

Somnolence has been reported with lisuride treatment.

Popular Posts

Category Medicinal Products, Next Article